{
    "2021-02-26": [
        [
            {
                "time": "",
                "original_text": "一年净赚33亿却难有话语权，HPV疫苗或纳入免疫规划，智飞生物难阻毛利率、增速双双下滑 盈利能力下降",
                "features": {
                    "keywords": [
                        "HPV疫苗",
                        "免疫规划",
                        "智飞生物",
                        "毛利率",
                        "增速下滑",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "疫苗股普遍造好，达安基因涨7%",
                "features": {
                    "keywords": [
                        "疫苗股",
                        "达安基因",
                        "涨幅"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业2020年报及2021年一季报业绩前瞻：2020分化巨大 21Q1恢复良好",
                "features": {
                    "keywords": [
                        "医药行业",
                        "年报",
                        "一季报",
                        "业绩",
                        "分化",
                        "恢复"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中泰证券：国内新冠病毒疫苗进入兑现期，关注有望首批兑现利润的相关企业",
                "features": {
                    "keywords": [
                        "中泰证券",
                        "新冠疫苗",
                        "兑现期",
                        "利润",
                        "相关企业"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}